31.60
0.01 (0.03%)
| Previous Close | 31.59 |
| Open | 31.65 |
| Volume | 460,635 |
| Avg. Volume (3M) | 303,387 |
| Market Cap | 2,208,199,424 |
| Price / Book | 8.51 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2026 |
| Diluted EPS (TTM) | -3.27 |
| Total Debt/Equity (MRQ) | 0.33% |
| Current Ratio (MRQ) | 11.10 |
| Operating Cash Flow (TTM) | -134.37 M |
| Levered Free Cash Flow (TTM) | -79.65 M |
| Return on Assets (TTM) | -31.88% |
| Return on Equity (TTM) | -52.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Pharvaris N.V. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.25% |
| % Held by Institutions | 89.49% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LU PENG | - | 31.46 | -226 | -7,104 |
| MODIG BERNDT | - | 31.54 | -2,291 | -72,258 |
| Aggregate Net Quantity | -2,517 | |||
| Aggregate Net Value ($) | -79,362 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 31.49 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MODIG BERNDT | Officer | 15 Jun 2026 | Automatic sell (-) | 2,291 | 31.54 | 72,258 |
| LU PENG | Officer | 12 Jun 2026 | Disposed (-) | 117 | 30.72 | 3,594 |
| LU PENG | Officer | 11 Jun 2026 | Disposed (-) | 109 | 32.20 | 3,510 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |